Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms STRATOS1
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 May 2020 Result (N=2016), of a pooled analysis of (SIROCCO, CALIMA, Phase IIb of Bernalizumab, Tralokinumab's STRATOS I, II and Phase IIb and tezepelumab Phase II PATHWAY) assessing clinical characteristics and biomarkers associated with exacerbation risk, presented at the 116th International Conference of the American Thoracic Society
    • 23 May 2018 Results of an analysis assessing the efficacy and safety of Tralokinumab in two phase III trials of severe, uncontrolled asthma (STRATOS 1 tralokinumab Q2W treatment group (all-comers N=398; FeNO-high N=92) and the STRATOS 2 FeNO-high cohort (N=108)), presented at the 114th International Conference of the American Thoracic Society.
    • 01 Nov 2017 According to an AstraZeneca media release, full data from the study will be presented at a forthcoming medical meeting.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top